This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción CTIC
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Competidores de CTI BioPharma Corp.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.09 |
| 52 Week High | US$9.10 |
| 52 Week Low | US$4.01 |
| Beta | 0.83 |
| 1 Month Change | 0.44% |
| 3 Month Change | 112.38% |
| 1 Year Change | 66.18% |
| 3 Year Change | 690.43% |
| 5 Year Change | 73.47% |
| Change since IPO | -99.99% |
Noticias y actualizaciones recientes
Recent updates
CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch
Aug 17CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M
Aug 08CTI BioPharma: Approval Is Great, Now There's The Follow Through
Jul 19CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis
Jul 07CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset
May 04CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating
Apr 11CTI BioPharma: A Speculative Buy Into The PDUFA Date
Mar 01CTI BioPharma: Long And Troubled History, Finally Approaching Approval
Dec 24FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA
Jun 01CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis
May 06CTI BioPharma: Accelerated Approval Pathway Looks Attractive
Dec 06Rentabilidad de los accionistas
| CTIC | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -0.1% | 0.1% | 2.2% |
| 1Y | 66.2% | -1.0% | 22.8% |
Rentabilidad vs. Industria: CTIC exceeded the US Biotechs industry which returned 7.4% over the past year.
Rentabilidad vs. Mercado: CTIC exceeded the US Market which returned 12% over the past year.
Volatilidad de los precios
| CTIC volatility | |
|---|---|
| CTIC Average Weekly Movement | 25.3% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: CTIC's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: CTIC's weekly volatility has increased from 15% to 25% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1991 | 128 | Adam Craig | www.ctibiopharma.com |
Resumen de fundamentos de CTI BioPharma Corp.
| Estadísticas fundamentales de CTIC | |
|---|---|
| Capitalización bursátil | US$1.20b |
| Beneficios(TTM) | -US$69.24m |
| Ingresos (TTM) | US$75.77m |
15.8x
Ratio precio-ventas (PS)-17.3x
Ratio precio-beneficio (PE)¿Está CTIC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CTIC | |
|---|---|
| Ingresos | US$75.77m |
| Coste de los ingresos | US$4.46m |
| Beneficio bruto | US$71.31m |
| Otros gastos | US$140.55m |
| Beneficios | -US$69.24m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.53 |
| Margen bruto | 94.11% |
| Margen de beneficio neto | -91.38% |
| Ratio deuda/patrimonio | -459.4% |
¿Cómo se ha desempeñado CTIC a largo plazo?
Ver rendimiento histórico y comparativa